Guardant Health, Inc. research snapshot
GH AI stock analysis currently sees Guardant Health as a fast-growing liquid-biopsy company whose Shield colorectal-cancer screening launch is becoming a material growth driver. First-quarter 2026 revenue rose 48% to $301.7 million, but the company still reported a $112.1 million GAAP net loss and $71.2 million free-cash-flow outflow. At the $164.08 July 9 close and about $21.76 billion calculated equity value, the GH AI stock forecast depends on screening adoption, reimbursement, oncology growth, cash discipline, and a credible route to profitability. This is scenario analysis for information only, not investment advice.
Current price
$164.08 close on July 9, 2026
Market cap
$21.76 billion calculated equity value
AI score
69 / 100
Rating
High-growth precision-oncology platform with a strong commercial catalyst and an unproven path to durable profitability
Trend status
Strong advance above the 50-day and 200-day averages, with elevated event and valuation risk
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Guardant sells blood-based oncology testing, colorectal-cancer screening, and biopharma data services, linking clinical testing volume to a recurring precision-medicine workflow. | High |
| Moat | Clinical evidence, regulatory and reimbursement work, laboratory operations, physician relationships, and accumulated molecular data create barriers, but larger diagnostics firms and other liquid-biopsy specialists compete for the same workflows. | Medium |
| Management | Management has expanded Shield and oncology commercialization while raising revenue guidance, but must prove that higher selling and marketing spending converts into durable unit economics. | Medium |
| Financial trend | FY2025 revenue grew 33% to $982.0 million. Q1 2026 revenue grew 48% to $301.7 million, while gross margin reached 65%; GAAP losses and negative free cash flow continue. | High |
| Valuation | At about $21.76 billion of equity value and 20.14x trailing sales, GH is valued on future scale rather than current profits. Negative EPS and free cash flow make P/E-based valuation unsuitable today. | High |
| Technical trend | The July 9 close of $164.08 was above the reported 50-day average of $122.83 and 200-day average of $100.03. RSI of 67.33 signals strong momentum with pullback risk. | Medium-high |
| Risk level | High. Reimbursement delays, clinical or regulatory setbacks, competition, rising commercialization costs, ongoing losses, dilution, and a sharp multiple reset can all affect the thesis. | High |
| AI confidence | Reported data are current and well documented, but forecast outcomes hinge on uncertain clinical adoption, payer behavior, and the pace of operating leverage. | High data confidence |
| Investment certainty | GH is not a high-certainty value setup because its current valuation requires continued exceptional execution before profitability is established. | Medium |
GH AI stock forecast
The GH AI stock forecast uses operating scenarios rather than a P/E model because Guardant has negative EPS and negative free cash flow. The required three-scenario P/E calculation was run with negative EPS and correctly produced non-economic zero values. The ranges below therefore reflect valuation sensitivity to revenue growth, screening adoption, gross margin, cash burn, and the timeline to profitability. They are scenarios, not price promises.
$180 to $220
More likely if Shield volumes and reimbursement expand faster than guidance, oncology test growth remains strong, 2026 revenue exceeds the $1.30 billion to $1.32 billion guide, gross margin holds, cash burn narrows, and investors continue to pay a premium for the screening opportunity.
$125 to $170
More likely if revenue meets guidance, Shield adoption grows but commercial spending remains high, oncology and biopharma growth stay healthy, and the market waits for clearer evidence of operating leverage.
$75 to $110
More likely if payer coverage or primary-care adoption disappoints, test reimbursement or clinical evidence weakens, expenses remain elevated, cash burn worsens, competitors gain share, or the sales multiple compresses.
GH AI technical analysis
GH AI technical analysis uses StockAnalysis market data available at the July 11, 2026 cutoff. The July 9 close was $164.08, above reported 50-day and 200-day moving averages of $122.83 and $100.03. This static page does not fetch request-time chart data, so confirm price, volume, moving averages, and momentum in a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $164.08 | July 9, 2026 close used for the market-cap verification. |
| Near support | $155 to $160 | A recent round-number monitoring area near the cutoff price, not a guaranteed floor. |
| Trend support | Near $122.83 | Reported 50-day moving average. A sustained move below it would weaken the medium-term trend. |
| Major support | Near $100.03 | Reported 200-day moving average. A sustained break would materially change the longer-term trend view. |
| Near resistance | $170 to $175 | A monitoring zone near the recent 52-week high of $174.08, not a prediction of a breakout. |
| Moving averages | 50-day $122.83, 200-day $100.03 | StockAnalysis values available around the cutoff and subject to change with each session. |
| Momentum | RSI 67.33 | Momentum was positive and approaching an extended reading; RSI alone is not a buy or sell signal. |
| Volume | About 3.57 million average shares over 20 days | Breakouts and breakdowns deserve more weight when volume is above the recent average. |
| Volatility | High | Earnings, payer news, regulatory events, clinical data, and valuation changes can move GH sharply. |
| Invalidation | Sustained close below $122.83 | A confirmed loss of the 50-day trend reference should trigger a review of price action and the underlying commercial thesis. |
GH AI trading strategy
The GH AI trading strategy is a rules-based research framework, not personalized advice. It combines live chart confirmation with test volumes, reimbursement, revenue growth, gross margin, cash burn, and risk controls.
Watch whether GH holds the $155 to $160 area and clears the $170 to $175 resistance zone on improving volume while the next results support Shield volumes, oncology growth, gross margin, and guidance.
A failed breakout or sustained close below the 50-day average near $122.83 should invalidate a trend setup before losses become open-ended.
If GH pulls back toward the 50-day average without deterioration in reimbursement, Shield test volumes, oncology volumes, guidance, or liquidity, compare the revised sales multiple with the operating path to profitability.
Do not average down solely because the price falls. Reassess if payer access, clinical evidence, pricing, gross margin, cash burn, or financing needs deteriorate.
Track oncology, screening, and biopharma revenue; Shield test volumes and payer coverage; reimbursement; gross margin; operating expenses; free cash flow; cash and debt; share count; and regulatory or clinical updates.
Position sizing should reflect that a fast-growing diagnostics narrative is not the same as proven, self-funding profitability.
Investment research summary
Customers pay Guardant for blood-based cancer tests that can inform treatment decisions, monitor recurrence, support screening, and provide molecular data and services to biopharma companies.
The moat rests on clinical validation, regulatory and reimbursement infrastructure, laboratory operations, relationships with clinicians and biopharma customers, and molecular data accumulated through testing. It can narrow if competing tests match clinical utility or payer access.
The thesis can fail if Shield adoption is slower or less reimbursed than expected, clinical outcomes disappoint, competition intensifies, commercial costs stay high, operating losses persist, funding needs dilute shareholders, or a premium sales multiple contracts.
Management is being tested on its ability to scale screening and oncology without allowing sales and marketing investment, laboratory capacity, and operating expenses to outrun gross-profit growth and liquidity.
Precision oncology and blood-based screening address a long-term need for earlier detection and more targeted treatment. The opportunity is large, but adoption is governed by clinical evidence, regulation, reimbursement, physician workflow, and patient access rather than technology alone.
At $164.08, the market is valuing future screening scale and operating leverage, not present earnings. Margin of safety would depend on a lower price while reimbursement, test-volume growth, gross margin, liquidity, and the route to profitability remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GH quote and market capitalization | $164.08 close on July 9, 2026; $21.76 billion market capitalization and 132.60 million shares outstanding | StockAnalysis statistics | July 11, 2026 |
| Market-cap verification | $21.76 billion calculated from $164.08 price and 132.60 million shares, with 0.01% variance to the reported value | StockAnalysis and financial_rigor.py market-cap verification | July 11, 2026 |
| FY2025 revenue and segment mix | $982.0 million revenue, including $683.6 million oncology, $210.1 million biopharma and data, and $79.7 million screening revenue | Guardant Health FY2025 results | July 11, 2026 |
| FY2025 revenue and net income cross-check | $982.0 million revenue and about $416 million GAAP net loss, cross-validated against Guardant Health, StockAnalysis, and Macrotrends | StockAnalysis financials and Macrotrends net-income history | July 11, 2026 |
| Q1 2026 operating data and guidance | $301.7 million revenue, 65% gross margin, $112.1 million GAAP net loss, $71.2 million free-cash-flow outflow, and $1.30 billion to $1.32 billion 2026 revenue guidance | Guardant Health Q1 2026 results | July 11, 2026 |
| Liquidity | $1.2 billion cash, cash equivalents, restricted cash, and marketable securities at March 31, 2026; company-reported year-end liquidity was $1.3 billion | Guardant Health Q1 2026 and FY2025 results | July 11, 2026 |
| Technical references | 50-day average $122.83, 200-day average $100.03, RSI 67.33, and 20-day average volume 3,565,320 shares | StockAnalysis statistics | July 11, 2026 |
| Valuation math | 20.14x trailing sales; P/E and P/FCF are not meaningful with negative earnings and free cash flow | StockAnalysis and financial_rigor.py valuation verification | July 11, 2026 |
This page is an informational research tool, not investment advice or a recommendation to buy or sell any security. Forecasts are scenarios based on available data and assumptions, may be wrong, and should be checked against current filings, prices, and professional advice before any decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
